COVID-19. Corona virus infection, unspecified
Conditions
Interventions
Intervention group: Patients in the main group recived Remdesivir consisting of two 100 mg vials, ie 200 mg intravenously, which is infused over a period of 30 minutes to two hours, on the first day
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age =18 years Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19 Severe pulmonary involvement in imaging that progresses despite receiving standard treatment protocols within 72 hours of starting antiviral therapy Oxygen saturation less than 90% with canola nasal or respiratory rate more than 30
Exclusion criteria
Exclusion criteria: Treatment with other antiviral drugs not listed in the national protocol Comorbidities such as malignancy, advanced heart failure, cirrhosis, dialysis patients, stroke, Alzheimer's, advanced neurological disease, progressive respiratory disease Allergic reaction to Remdesivir Pregnant or lactating women Possibility of transfer to another hospital that does not have access to study drugs Evidence of multiple organ failure Receive any experimental treatment for Covid 19 Patients under mechanical ventilation at the beginning of the study Alanine Aminotransferase or Aspartate Aminotransferase more than 5 times normal Creatinine clearance less than 50 ml per minute
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of stay. Timepoint: The first day and the last day of the patient's hospitalization. Method of measurement: patient file.;Oxygen Saturation. Timepoint: Daily. Method of measurement: Pulls oximeter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: Daily. Method of measurement: Thermometer.;Dyspnea. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Cough. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Respiratory Rate. Timepoint: Daily. Method of measurement: Patients interview and patient file.;C-Reactive protein. Timepoint: The first day and the seventh day of study. Method of measurement: Agglutination kit.;Lymphocyte blood count. Timepoint: The first day and the seventh day of study. Method of measurement: Cell counter.;Alanine Amino Transferase. Timepoint: The first day and the seventh day of study. Method of measurement: Determination of enzyme in serum by biochemical method.;Aspartate Aminotransferase. Timepoint: The first day and the seventh day of study. Method of measurement: Determination of enzyme in serum by biochemical method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRoohangiz Nashibi
Ahvaz University of Medical Sciences
Outcome results
None listed